Oxford BioMedica Reports ProSavin Promise In Two-Year Study
14th Jun 2010 09:22
LONDON (Dow Jones)--Biotechnology company Oxford BioMedica PLC (OXB.LN) Monday said two patients in a three-patient study of its experimental Parkinson's disease medicine ProSavin demonstrated a 30% improvement in motor function two years after getting treatment. The results of the two-year foll
Read moreOxford BioMedica says Parkinson's drug 'promising'
14th Jun 2010 08:18
Oxford BioMedica's ongoing Phase I/II trial of its ProSavin drug to treat Parkinson's disease has shown "sustained" improvements in patients. Follow-up data suggests that patients continued to benefit from ProSavin after two years and that ProSavin was safe and well tolerated. Of the first cohort
Read moreTechMARK movers: Ark seeks partners
5th May 2010 15:03
Cancer treatments developer Ark Therapeutics has completed its strategic review and this has been received positively by the market. Ark intends to change its strategy to selective partnering of drug programmes. That should help Ark to preserve cash until the second half of 2011. Ark has replaced
Read moreTechMARK movers: NXT disappoints
27th Apr 2010 14:40
Flat speaker technology developer NXT says revenues have been below expectations since the beginning of 2010. New product delays have not helped and those products that were launched had disappointing sales. Royalty revenues from portable speakers were lower than expected. NXT needs to sign additi
Read moreSmall caps round-up: 32Red, Alkane, Norseman...
10th Mar 2010 11:21
Online casino operator 32Red enjoyed a "strong" recovery in the second half and said revenues increased 10% in January and February. Profit before tax fell to £530,186 in 2009 from £1.27m a year ago on revenue down 2% to £12.75m. The 32Red Casino business led the fight back, helping total second ha
Read moreThursday tips round-up: Wetherspoon, Soco, Character
21st Jan 2010 06:01
The economic backdrop remains tough but Wetherspoon's value-for-money offer and unmatched retail skills will ensure that it is among the winners. At 463p, or 13 times earnings, hold on for recovery, advises the Times. The Independent agrees and says the shares are too pricey to recommend buying more
Read moreOxford boosted by EMA oprhan drug designation
20th Jan 2010 08:42
Gene therapy company Oxford Biomedica said UshStat, its treatement for Usher syndrome 1B, has received orphan designation from the Committee for Orphan Medicinal Products of the European Medicines Agency. Companies with European orphan drug designation benefit from incentives, including ten years
Read moreLondon close: Blue chips falter after recent strength
15th Oct 2009 16:38
London closed lower as bumper profits at US investment bank Goldman Sachs failed to spark Wall Street, which has retreated from the 10,000 mark hit last night. Goldman Sachs reported quarterly earnings per share of $5.25 versus the $4.24 predicted. Revenue of $12.37bn was much better than the $11.0
Read moreLondon afternoon: Stocks stuck in red
15th Oct 2009 15:13
Bumper profits at US investment bank Goldman Sachs have failed to ignite fresh buying interest on Wall Street, leaving London weaker as resource plays struggle. Goldman Sachs pitched in with forecast-busting third quarter numbers, but that's not been enough to extend the Dow's gains above 10,000. T
Read moreTechMARK movers: Oxford Bio jumps on trial
15th Oct 2009 12:35
Oxford Biomedica doubled at one stage Thursday after it said patients taking part in a Phase I/II trial of its Parkinson's disease drug ProSavin have shown further improvement in motor function. A six-month assessment at the second dose level has been completed and boss John Dawson says there's now
Read moreLondon midday: Sainsbury's soars on Qatar rumours
15th Oct 2009 12:12
J Sainsbury is the stand-out riser so far on talk that the Qatar investors in the supermarket are looking to build on their current 26% stake, but it is no more than rumours so far. Otherwise Footsie is marking time, but that could change after bumper figures from Goldman Sachs. The banking giant r
Read moreOxford Biomedica doubles on Parkinson's success
15th Oct 2009 10:15
Oxford Biomedica doubled at one stage Thursday after it said patients taking part in a Phase I/II trial of its Parkinson's disease drug ProSavin have shown further improvement in motor function. A six-month assessment at the second dose level has been completed and boss John Dawson says there's now
Read moreTechMARK movers: Oxford Bio down after update
22nd Sep 2009 11:34
Shares in Oxford BioMedica dropped after interim results from a Phase III study of the gene therapy company's cancer vaccine TroVax did not show a 'significant' survival advantage compared to placebo in the total population. 'Although I am disappointed that the trial did not meet its primary endpoi
Read moreTechMARK movers: GB and Oxford Biomedica drop
13th Jul 2009 12:37
Identity management specialists GB Group was slightly lower despite saying that interim pre-tax profit was marginally ahead of the same period last year. Profit before taxation stood at £135,000 for the interim period to 13 July 2009 compared with £41,000 the same time a year earlier. Revenue for t
Read moreTechMARK movers: Alizyme chief exec steps down
6th Jul 2009 14:21
Alizyme has lost chief executive Tim McCarthy as part of the drug developer's reconstruction effort. Non-executive director Alan Goodman will take charge of the day to day affairs of the business after McCarthy stepped down with immediate effect. The US Food and Drug Administration (FDA) has clear
Read more